NUCB1 and cancer: Our current study evaluated the significance of disparities in the levels of ANA, anti-dsDNA, anti-Sm, anti-RO52, anti-RO60, anti-SSB, anti-Nuc, anti-His, anti-Rib, and anti-nRNP antibodies between the cancer group and the cancer-free control group at the time of cancer diagnosis.